New Treatment for Childhood Arthritis

Friday, 10 May 2013 11:47 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Novartis said the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.

Ilaris inhibits interleukin-1 beta, excessive production of which plays a prominent role in certain inflammatory diseases, the company said.

The drug is the only approved treatment specifically for the condition that can be given as a monthly subcutaneous injection, Novartis said.

Ilaris is also approved in the European Union for the treatment of refractory gouty arthritis, Novartis said.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

New Test Diagnoses Type 1 Diabetes

Wednesday, 27 Aug 2014 12:36 PM

The U.S. Food and Drug Administration has approved a new test that may help doctors diagnose type 1 diabetes, the most c . . .

Help for Gaucher's Disease

Wednesday, 20 Aug 2014 12:30 PM

The Food and Drug Administration on Tuesday approved a new capsule-based drug to treat Gaucher's disease.
Regulato . . .

Insomnia Drug Regulates Sleep/Wake Cycle

Thursday, 14 Aug 2014 10:14 AM

A new prescription insomnia drug that's the first of its kind was approved by the U.S. Food and Drug Administration on W . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved